$GBT
Global Blood Therapeutics Inc.
PRICE
$68.48 ▼-0.015%
Extented Hours
VOLUME
3,279,961
DAY RANGE
68.47 - 68.49
52 WEEK
0 - 68.49
Key Metrics
Market Cap
0
Beta
0
Avg. Volume
0
Shares Outstanding
67.48 M
Yield
0%
Public Float
0
Next Earnings Date
Next Dividend Date
Company Information
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
CEO: Ted Love
Website: www.globalbloodtx.com
HQ: 181 Oyster Point Blvd South San Francisco, 94080 California
Related News